Press
VC Firm Bioluminescence Ventures Launches with $477M in Assets • Biospace
Media Coverage
|
1 November 2023
ReCode raises $50 million to support developing mRNA therapies • Cystic Fibrosis News Today
Media Coverage
|
22 September 2023
ReCode Raises $260M in Series B Financing to Advance Lead Programs • Biospace
Media Coverage
|
20 September 2023
ReCode Therapeutics Announces Closing of Extension to Series B Financing
Press Releases
|
19 September 2023
ReCode Therapeutics Raises Additional USD50M in Series B Financing • FinSMEs
Media Coverage
|
19 September 2023
NIDO-361 by Nido Biosciences for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy): Likelihood of Approval • Pharmaceutical Technology
Media Coverage
|
11 September 2023